AU4930001A - Cold-adapted equine influenza viruses - Google Patents

Cold-adapted equine influenza viruses

Info

Publication number
AU4930001A
AU4930001A AU4930001A AU4930001A AU4930001A AU 4930001 A AU4930001 A AU 4930001A AU 4930001 A AU4930001 A AU 4930001A AU 4930001 A AU4930001 A AU 4930001A AU 4930001 A AU4930001 A AU 4930001A
Authority
AU
Australia
Prior art keywords
viruses
cold
equine influenza
influenza virus
influenza
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU4930001A
Inventor
Patricia W Dowling
Julius S Youngner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pittsburgh
Original Assignee
University of Pittsburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pittsburgh filed Critical University of Pittsburgh
Publication of AU4930001A publication Critical patent/AU4930001A/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16161—Methods of inactivation or attenuation
    • C12N2760/16164—Methods of inactivation or attenuation by serial passage

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides experimentally-generated cold-adapted equine influenza viruses, and reassortant influenza A viruses comprising at least one genome segment of such an equine influenza virus, wherein the equine influenza virus genome segment confers at least one identifying phenotype of the cold-adapted equine influenza virus, such as cold-adaptation, temperature sensitivity, dominant interference, or attenuation. Such viruses are formulated into therapeutic compositions to protect animals from diseases caused by influenza A viruses, and in particular, to protect horses from disease caused by equine influenza virus. The present invention also includes methods to protect animals from diseases caused by influenza A virus or other infectious agents utilizing the claimed therapeutic compositions. Such methods include using a therapeutic composition as a vaccine to generate a protective immune response in an animal prior to exposure to an infectious agent, as well as using a therapeutic composition as a treatment for an animal that has been recently infected with an infectious agent leading to respiratory disease, or is likely to be subsequently exposed to such an agent in a few days whereby the therapeutic composition reduces such respiratory disease, even in the absence of antibody-mediated immunity. The present invention also provides methods to produce cold-adapted equine influenza viruses, and reassortant influenza A viruses having at least one genome segment of an equine influenza virus generated by cold-adaptation.
AU4930001A 2000-04-03 2001-03-21 Cold-adapted equine influenza viruses Pending AU4930001A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19432500P 2000-04-03 2000-04-03
PCT/US2001/008968 WO2001074386A2 (en) 2000-04-03 2001-03-21 Cold-adapted equine influenza viruses

Publications (1)

Publication Number Publication Date
AU4930001A true AU4930001A (en) 2001-10-15

Family

ID=22717146

Family Applications (2)

Application Number Title Priority Date Filing Date
AU4930001A Pending AU4930001A (en) 2000-04-03 2001-03-21 Cold-adapted equine influenza viruses
AU2001249300A Expired AU2001249300B2 (en) 2000-04-03 2001-03-21 Cold-adapted equine influenza viruses

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2001249300A Expired AU2001249300B2 (en) 2000-04-03 2001-03-21 Cold-adapted equine influenza viruses

Country Status (8)

Country Link
US (2) US7029903B2 (en)
EP (1) EP1267920B1 (en)
JP (1) JP2003528925A (en)
AT (1) ATE350056T1 (en)
AU (2) AU4930001A (en)
CA (1) CA2403979A1 (en)
DE (1) DE60125736D1 (en)
WO (1) WO2001074386A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004003572A1 (en) 2004-01-23 2005-08-18 Bavarian Nordic A/S Monoparamunity inducers based on attenuated rabbit myxomaviruses
US7572620B2 (en) 2005-01-11 2009-08-11 Wisconsin Alumni Research Foundation H3 equine influenza A virus
US11865172B2 (en) 2005-04-21 2024-01-09 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
US7959929B2 (en) 2005-04-21 2011-06-14 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
US8647637B2 (en) 2009-01-30 2014-02-11 The Board Of Regents For Oklahoma State University Immunogenic compositions, vaccines and diagnostics based on canine distemper viruses circulating in north american dogs
WO2010111687A2 (en) 2009-03-27 2010-09-30 Academia Sinica Methods and compositions for immunization against virus
CA2791396C (en) * 2010-03-10 2019-08-27 Intervet International B.V. Method for protecting against disease caused by secondary pathogens
TWI537385B (en) * 2010-11-04 2016-06-11 中央研究院 Methods for producing virus particles with simplified glycosylation of surface proteins
JP6313752B2 (en) * 2012-05-31 2018-04-18 ゾエティス・エルエルシー B. Vaccination with canine respiratory coronavirus to protect against B. bronchiseptica infection
JP6560056B2 (en) * 2015-08-07 2019-08-14 ウィスコンシン アルムニ リサーチ ファンデイション H3 equine influenza A virus

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3518347A (en) 1965-05-28 1970-06-30 Inst Microbiologie Et D Hygien Vaccine for equine influenza
US3992522A (en) 1973-01-24 1976-11-16 The United States Of America As Represented By The Department Of Health, Education And Welfare Temperature-sensitive recombinant mutant viruses and a process for producing same
CA1204069A (en) 1982-04-16 1986-05-06 Cornell Research Foundation, Inc. Temperature sensitive reassortant viruses and a vaccine against equine influenza
US4683137A (en) 1982-04-16 1987-07-28 Cornell Research Foundation, Inc. Temperature sensitive reassortant viruses and a vaccine against equine influenza
GB8300467D0 (en) 1983-01-08 1983-02-09 Wellcome Found Equine influenza
US4631191A (en) 1985-06-20 1986-12-23 Biotechnology Research Partners, Ltd. Methods and compositions useful in preventing equine influenza
US4920213A (en) 1985-06-20 1990-04-24 Biotechnology Research Partners, Ltd. Method and compositions useful in preventing equine influenza
US5149531A (en) 1990-06-27 1992-09-22 University Of Pittsburgh Of The Commonwealth System Of Higher Education Method of using cold-adapted live influenza virus vaccine as an antiviral agent against influenza
IL105456A (en) 1992-04-21 1996-12-05 American Home Prod Attenuated respiratory syncytial virus vaccine compositions
US5690937A (en) 1995-06-05 1997-11-25 Aviron Temperature sensitive clustered changed-to-alanine mutants of influenza virus PB2 gene
US6177082B1 (en) 1998-08-13 2001-01-23 The University Of Pittsburgh-Of The Commonwealth System Of Higher Education Cold-adapted equine influenza viruses

Also Published As

Publication number Publication date
US20040223980A1 (en) 2004-11-11
US20060121521A1 (en) 2006-06-08
EP1267920A2 (en) 2003-01-02
EP1267920B1 (en) 2007-01-03
DE60125736D1 (en) 2007-02-15
ATE350056T1 (en) 2007-01-15
AU2001249300B2 (en) 2006-02-16
WO2001074386A3 (en) 2002-05-23
CA2403979A1 (en) 2001-10-11
US7029903B2 (en) 2006-04-18
WO2001074386A2 (en) 2001-10-11
JP2003528925A (en) 2003-09-30

Similar Documents

Publication Publication Date Title
ATE358722T1 (en) COLD-ADAPTABLE HORSES INFLUENZA VIRUSES
WO2001060849A3 (en) Cold-adapted equine influenza viruses
TW200730188A (en) Vaccines and methods to treat canine influenza
NO20061912L (en) Vaccine compositions comprising an interleukin 18 and saponin adjuvant system
UA41315C2 (en) VACCINE COMPOSITION AGAINST RESPIRATORY-SYNCITIAL VIRUS, METHOD OF STIMULATION OF INDIVIDUAL'S IMMUNE SYSTEM FOR INDUSTRIAL INDUCTION
CO5611162A2 (en) METHODS TO PREVENT REPRODUCTIVE DISEASES IN VACCINE LIVESTOCK
AU4930001A (en) Cold-adapted equine influenza viruses
EP2078083A4 (en) A novel canine influenza virus and vaccine therefore
MXPA02004627A (en) Vaccines for mycoplasma bovis.
JP2007197470A5 (en)
MX2022010373A (en) Vaccine against african swine fever virus infection.
AU9215101A (en) Vaccines containing ribavirin and methods of use thereof
WO2007036735A3 (en) Immunogenic agents againts burkholderia psudomallei and/or burkholderia mallei, comprising lipopolysaccharide, capsular polysaccharide and/or proteins from burkholderia psuedomallei
WO2004043404A3 (en) Process for designing inhibitors of influenza virus non-structural protein 1
MXPA03009763A (en) Foot and mouth disease virus vaccine.
JP2003528925A5 (en)
WO2007135420A3 (en) Defective interfering virus
HUP9700975A2 (en) Live attenuated rtx-producing bacteria of the family pasteurellaceae
YU65102A (en) In ovo protection against infectious bronchitis
DK1132466T3 (en) Chicken anemia virus with low pathogenicity
Thomson et al. Foot and Mouth Disease in Southern Africa: Re-evaluation of the approach to control
HUP0202738A2 (en) Equine herpes virus temperature sensitive mutant and live vaccine thereof
NO20014372D0 (en) Isolation and partial characterization of a novel antiprocferative component from human leukocytes
Kirkbride et al. Rabies risk from contact with bats
HUP0402548A2 (en) An avian embryo particulate biomass for the production of virus antigens